Company Earnings UpdateCVS Health (NYSE: CVS) 2Q19 Results: Narrows Profit and Earnings Outlook on Aetna Strength Coresight Research August 9, 2019 Executive Summary CVS Health reported 2Q19 revenues of $63.4 billion, up 35.2% year over year and ahead of the consensus estimate. Diluted EPS was $1.49, versus a loss per share of $2.52 in 2Q18. CVS closed its acquisition of Aetna in November 2018 and was the primary growth driver during the quarter, along with increased volumes and brand name drug price inflation. For FY19, CVS narrowed its adjusted EPS guidance range to $6.89-7.00 from $6.75-6.90. Please Login to read the full report. Not a member? To access this content for free, register for a free account. This document was generated for Other research you may be interested in: Analyst Corner: The Labubu Craze—Revealing How Gens Z and Alpha Are Redefining Retail, with Charlie PoonConsumer Confidence Rebounds in October: China Consumer Survey InsightsThe Evolving Supply Chain Landscape: Tariffs, Holiday 2025, and What’s Next: Insights Presented by Deborah Weinswig at The Lead SummitHigher-Income Sentiment Improves; Holiday Shopping Is Firmly Under Way: US Consumer Survey Insights
